Loading clinical trials...
Loading clinical trials...
Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE
Conditions
Locations
222
United States
Cardiovascular Innovation and Research Center
Long Beach, California, United States
Health and Life Research Institute, LLC
Miami, Florida, United States
Med-Care Research
Miami, Florida, United States
Pines Care Research Center
Pembroke Pines, Florida, United States
Tampa General Hospital
Tampa, Florida, United States
Ellipsis Group
Atlanta, Georgia, United States
Start Date
November 5, 2015
Primary Completion Date
March 31, 2019
Completion Date
March 31, 2019
Last Updated
April 29, 2020
NCT06189313
NCT07015905
NCT03728166
NCT07310693
NCT07288632
NCT06451003
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions